Gerber DE - Search Results

1

T-cell tolerant fraction as a predictor of immune-related adverse events.

Ostmeyer J, Park JY, von Itzstein MS, Hsiehchen D, Fattah F, Gwin M, Catalan R, Khan S, Raj P, Wakeland EK, Xie Y, Gerber DE. Ostmeyer J, et al. Among authors: gerber de. J Immunother Cancer. 2023 Aug;11(8):e006437. doi: 10.1136/jitc-2022-006437. J Immunother Cancer. 2023. PMID: 37580069 Free PMC article.

2

The impact of consenter characteristics and experience on patient interest in clinical research.

Rasco DW, Xie Y, Yan J, Sayne JR, Skinner CS, Dowell JE, Gerber DE. Rasco DW, et al. Among authors: gerber de. Oncologist. 2009 May;14(5):468-75. doi: 10.1634/theoncologist.2008-0268. Epub 2009 Apr 28. Oncologist. 2009. PMID: 19401521 Free article.

3

Lung cancer diagnostic and treatment intervals in the United States: a health care disparity?

Yorio JT, Xie Y, Yan J, Gerber DE. Yorio JT, et al. Among authors: gerber de. J Thorac Oncol. 2009 Nov;4(11):1322-30. doi: 10.1097/JTO.0b013e3181bbb130. J Thorac Oncol. 2009. PMID: 19752757 Free PMC article.

4

Looking beyond surveillance, epidemiology, and end results: patterns of chemotherapy administration for advanced non-small cell lung cancer in a contemporary, diverse population.

Rasco DW, Yan J, Xie Y, Dowell JE, Gerber DE. Rasco DW, et al. Among authors: gerber de. J Thorac Oncol. 2010 Oct;5(10):1529-35. doi: 10.1097/JTO.0b013e3181e9a00f. J Thorac Oncol. 2010. PMID: 20631635 Free PMC article. Clinical Trial.

5

Predictors and impact of second-line chemotherapy for advanced non-small cell lung cancer in the United States: real-world considerations for maintenance therapy.

Gerber DE, Rasco DW, Le P, Yan J, Dowell JE, Xie Y. Gerber DE, et al. J Thorac Oncol. 2011 Feb;6(2):365-71. doi: 10.1097/JTO.0b013e3181fff142. J Thorac Oncol. 2011. PMID: 21173713 Free PMC article.

6

Development of bavituximab, a vascular targeting agent with immune-modulating properties, for lung cancer treatment.

DeRose P, Thorpe PE, Gerber DE. DeRose P, et al. Among authors: gerber de. Immunotherapy. 2011 Aug;3(8):933-44. doi: 10.2217/imt.11.87. Immunotherapy. 2011. PMID: 21843081 Review.

7

Socioeconomic disparities in lung cancer treatment and outcomes persist within a single academic medical center.

Yorio JT, Yan J, Xie Y, Gerber DE. Yorio JT, et al. Among authors: gerber de. Clin Lung Cancer. 2012 Nov;13(6):448-57. doi: 10.1016/j.cllc.2012.03.002. Epub 2012 Apr 17. Clin Lung Cancer. 2012. PMID: 22512997 Free PMC article.

8

A multicenter phase II study of cisplatin, pemetrexed, and bevacizumab in patients with advanced malignant mesothelioma.

Dowell JE, Dunphy FR, Taub RN, Gerber DE, Ngov L, Yan J, Xie Y, Kindler HL. Dowell JE, et al. Among authors: gerber de. Lung Cancer. 2012 Sep;77(3):567-71. doi: 10.1016/j.lungcan.2012.05.111. Epub 2012 Jul 4. Lung Cancer. 2012. PMID: 22770372 Clinical Trial.

9

Consent timing and experience: modifiable factors that may influence interest in clinical research.

Gerber DE, Rasco DW, Skinner CS, Dowell JE, Yan J, Sayne JR, Xie Y. Gerber DE, et al. J Oncol Pract. 2012 Mar;8(2):91-6. doi: 10.1200/JOP.2011.000335. Epub 2011 Dec 6. J Oncol Pract. 2012. PMID: 23077435 Free PMC article.

10

Influence of medical comorbidities on the presentation and outcomes of stage I-III non-small-cell lung cancer.

Ahn DH, Mehta N, Yorio JT, Xie Y, Yan J, Gerber DE. Ahn DH, et al. Among authors: gerber de. Clin Lung Cancer. 2013 Nov;14(6):644-50. doi: 10.1016/j.cllc.2013.06.009. Epub 2013 Jul 22. Clin Lung Cancer. 2013. PMID: 23886797 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

262 results

Search Page

Filters